Acute interstitial nephritis and PR3-ANCA following reintroduction of pembrolizumab: a case report.


Journal

Immunotherapy
ISSN: 1750-7448
Titre abrégé: Immunotherapy
Pays: England
ID NLM: 101485158

Informations de publication

Date de publication:
03 2021
Historique:
pubmed: 6 1 2021
medline: 3 2 2022
entrez: 5 1 2021
Statut: ppublish

Résumé

Renal toxicity from immune checkpoint inhibitors (ICIs) is an increasingly recognized cause of acute kidney injury among patients with cancer. ICI-associated acute kidney injuries typically present as acute interstitial nephritis and the timing of onset is highly variable. Herein, we present a case of a patient with relapsed metastatic melanoma previously treated with pembrolizumab who developed grade 3 immune-related renal toxicity after reintroduction of the same ICI, secondary to acute interstitial nephritis with accompanying high PR3-antineutrophil cytoplasmic antibody titer. The patient improved after steroid treatment and discontinuation of pembrolizumab. This case highlights the importance of not excluding ICI-related nephrotoxicity as a possible cause of renal failure, including in those who previously tolerated ICI treatment, since it is a treatable entity.

Identifiants

pubmed: 33397120
doi: 10.2217/imt-2020-0223
doi:

Substances chimiques

Antibodies, Antineutrophil Cytoplasmic 0
Antibodies, Monoclonal, Humanized 0
B7-H1 Antigen 0
Immune Checkpoint Inhibitors 0
Steroids 0
pembrolizumab DPT0O3T46P

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

283-288

Auteurs

Matthew Mulroy (M)

Department of Medicine, University of California, Los Angeles, CA 90095, USA.

Sanaz Ghafouri (S)

Department of Medicine, University of California, Los Angeles, CA 90095, USA.

Anthony Sisk (A)

Department of Pathology, University of California, Los Angeles, CA 90095, USA.

Antoni Ribas (A)

Department of Medicine, University of California, Los Angeles, CA 90095, USA.

Ray Goshtaseb (R)

Department of Medicine, University of California, Los Angeles, CA 90095, USA.

Grace Cherry (G)

Department of Medicine, University of California, Los Angeles, CA 90095, USA.

John Shen (J)

Department of Medicine, University of California, Los Angeles, CA 90095, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH